Response assessment in neuro-oncology (RANO) criteria: application in clinical research and routine practice
- Авторлар: Kobyakova E.A1, Usachev D.Y.2, Absalyamova O.V2, Kobyakov G.L.3, Lodygina K.S2, Belyaev A.Y.2, Trunin Y.Y.2, Belyashova A.S2, Kobyakov G.L2
-
Мекемелер:
- N.N. Blokhin National Medical Research Center of Oncology
- Burdenko National Medical Research Center of Neurosurgery
- Lomonosov Moscow State University
- Шығарылым: Том 28, № 11 (2021)
- Беттер: 21-33
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313273
- DOI: https://doi.org/10.18565/pharmateca.2021.11.21-33
- ID: 313273
Дәйексөз келтіру
Аннотация
Негізгі сөздер
Толық мәтін
Авторлар туралы
E. Kobyakova
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
D. Usachev
Burdenko National Medical Research Center of NeurosurgeryMoscow, Russia
O. Absalyamova
Burdenko National Medical Research Center of NeurosurgeryMoscow, Russia
Grigory Kobyakov
Lomonosov Moscow State University
Email: gkobiakov@nsi.ru
Moscow, Russia
K. Lodygina
Burdenko National Medical Research Center of NeurosurgeryMoscow, Russia
A. Belyaev
Burdenko National Medical Research Center of NeurosurgeryMoscow, Russia
Yu. Trunin
Burdenko National Medical Research Center of NeurosurgeryMoscow, Russia
A. Belyashova
Burdenko National Medical Research Center of NeurosurgeryMoscow, Russia
G. Kobyakov
Burdenko National Medical Research Center of NeurosurgeryMoscow, Russia
Әдебиет тізімі
- Chukwueke U.N., Wen P.Y. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019;8(1):CNS28. doi: 10.2217/cns-2018-0007.
- Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16. doi: 10.1093/jnci/92.3.205.
- Eisenhauer E.A., Therasse P, Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. Doi: 10.1016/j. ejca.2008.10.026.
- Кобяков Г.Л. Химиотерапия в комплексном лечении больных с супратенториальными злокачественными внутримозговыми опухолями (14.00.28 - нейрохирургия, 14.00.14 -онкология). Дисс. канд. мед. наук. М., 1998
- Клинические рекомендации «Первичные опухоли центральной нервной системы» (утверждены Минздравом РФвноябре 2018 г)
- Клинические рекомендации «Первичные опухоли центральной нервной системы» (утверждены Минздравом РФвфеврале 2020 г)
- Schwartz L.H., Litiere S., de Vries E., et al. (2016). RECIST 1.1-Update and clarification: From the RECIST committee. European journal of cancer (Oxford, England). 1990;62:132-137. URL: https://doi.org/10.1016/j.ejca.2016.03.081.
- Macdonald D.R., Cascino T.L., Schold S.C. Jr., Cairncross J.G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-80. Doi: 10.1200/ JCO.1990.8.7.1277.
- Wen P.Y, Chang S.M., Van den Bent M.J., et al. Response assessment in neuro-oncology clinical trials. J Clin Oncol. 2017;35(21):2439-49. doi: 10.1200/JCO.2017.72.7511.
- van den Bent M.J., Vogelbaum M.A., Wen P.Y., et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009;27(18):2905-908. doi: 10.1200/JCO.2009.22.4998.
- Vredenburgh J.J., Desjardins A., Herndon J.E. II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-29. Doi: 10.1200/ JCO.2007.12.2440.
- Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-40. Doi: 10.1200/ JCO.2008.19.8721.
- Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agentbevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-45. doi: 10.1200/JCO.2008.16.3055.
- Gutin P.H., Iwamoto F.M., Beal K., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156-doi: 10.1016/j.ijrobp.2008.10.043.
- Lai A., Tran A., Nghiemphu P.L., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142-48. Doi: 10.1200/ JCO.2010.30.2729.
- Xu T., Chen J., Lu Y., Wolff J.E. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer. 2010;10:252. doi: 10.1186/1471-2407-10252.
- Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-72. Doi: 10.1200/ JCO.2009.26.3541.
- Henson J.W., Ulmer S., Harris G.J. Brain tumor imaging in clinical trials. AJNR. Am J Neuroradiol. 2008;29(3):419-24. doi: 10.3174/ajnr.A0963.
- URL: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
- URL: https://www.eano.eu/publications/eano-guidelines/
- van den Bent M.J., Smits M., Kros J.M. et al. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol. 2017;35(21):2394-401. doi: 10.1200/JCO.2017.72.6737.
- Avila E.K., Chamberlain M., Schiff D., et al. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro Oncol. 2017;19(1):12-21. Doi: 10.1093/ neuonc/now190.
- Berghoff A.S., Brastianos P.K. Toward precision medicine in brain metastases. Semin Neurol. 2018;38(1):95-103. doi: 10.1055/s-0038-1627469.
- Chukwueke U.N., Wen PY. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019;8(1):CNS28. doi: 10.2217/cns-2018-0007.
- Chamberlain M., Junck L., Brandsma D., et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2017;19(4):484-doi: 10.1093/neuonc/now183.
- Nayak L., De Angelis L.M., Brandes A.A., et al. Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017;19(5):625-35. doi: 10.1093/neuonc/ nox029.
- Kesari S., Batchelor T.T. Leptomeningeal metastases. Neurol Clin. 2003;21(1):25-66. Doi: 10.1016/ s0733-8619(02)00032-4.
- Le Rhun E, Weller M, Brandsma D et al. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28(Suppl. 4):iv84-iv99. doi: 10.1093/annonc/mdx221.
- Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624.
- Arvold N.D., Armstrong T.S., Warren K.E., et al. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology working group. Neuro Oncol. 2018;20(7):897-906. doi: 10.1093/neuonc/noy056.
- Albert N.L., Weller M., Suchorska B., et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199-208. doi: 10.1093/neuonc/ now058.
- Galldiks N., Albert N.L., Sommerauer M., et al. PET imaging in patients with meningioma-report of the RANO/PET group. Neuro Oncol. 2017;19(12):1576-87. doi: 10.1093/neuonc/ nox112.
- Law I., Albert N.L, Arbizu J., et al. Joint EANM/ EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F] FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540-57. doi: 10.1007/s00259-018-4207-9.
- Warren K.E., Poussaint T.Y., Vezina G., et al. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neurooncology (RAPNO) working group. Pediatr Blood Cancer. 2013;60(9):1397-401. Doi: 10.1002/ pbc.24562.
- Fangusaro J., Witt O., Driever P.H., et al. IMG- 03. Response assessment in pediatric low-grade glioma: recommendations from the response assessment in pediatric neuro-oncology (RAPNO) working group. Neuro Oncol. 2020;22(Suppl 3):iii355. doi: 10.1093/neuonc/noaa222.339.
- Louis D.N., Perry A., Reifenberger G., et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803-20. doi: 10.1007/s00401-016-1545-1.